VALTOCO (diazepam) by Neurelis is mechanism of action although the precise mechanism by which diazepam exerts its antiseizure effects is unknown, animal and in vitro studies suggest that diazepam acts to suppress seizures through an interaction with γ-aminobutyric acid (gaba) receptors of the a-type (gaba a ). Approved for epilepsy, alcohol withdrawal syndrome, seizures. First approved in 2020.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
VALTOCO is a nasal spray formulation of diazepam, a benzodiazepine approved by the FDA in January 2020 for the treatment of epilepsy. The drug works by enhancing the action of GABA, the brain's primary inhibitory neurotransmitter, which reduces neuronal excitability and prevents seizure generation and spread. This novel nasal delivery system offers an alternative to traditional oral or injectable diazepam formulations, providing rapid onset of action for acute seizure management.
Mechanism of Action Although the precise mechanism by which diazepam exerts its antiseizure effects is unknown, animal and in vitro studies suggest that diazepam acts to suppress seizures through an interaction with γ-aminobutyric acid (GABA) receptors of the A-type (GABA A ). GABA, the major…
Benzodiazepine
Worked on VALTOCO at Neurelis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán
Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moVALTOCO's nasal delivery platform and specialty epilepsy positioning create roles for specialty brand managers, neurology-focused medical science liaisons, and hospital/specialty pharmacy teams. Success in this role requires deep understanding of benzodiazepine pharmacology, seizure management protocols, and healthcare provider education in specialty neurology settings. Currently 1 linked job opening is associated with this product in the employment market.